|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Ota S, Ishii G, Goto K, et al:
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen
predicts survival in advanced non-small-cell lung cancer treated
with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kajiyama H, Shibata K, Terauchi M, et al:
Chemoresistance to paclitaxel induces epithelial mesenchymal
transition and enhances metastatic potential for epithelial ovarian
carcinoma cells. Int J Oncol. 31:277–283. 2007.
|
|
4
|
Yang AD, Fan F, Camp ER, et al: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hiscox S, Jiang WG, Obermeier K, et al:
Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and
involves modulation of β-catenin phosphorylation. Int J Cancer.
118:290–301. 2006.PubMed/NCBI
|
|
6
|
Hiscox S, Morgan L, Barrow D, Dutkowskil
C, Wakeling A and Nicholson RI: Tamoxifen resistance in breast
cancer cells is accompanied by an enhanced motile and invasive
phenotype: inhibition by gefitinib (‘Iressa’, ZD1839). Clin Exp
Metastasis. 21:201–212. 2004.PubMed/NCBI
|
|
7
|
Chang CJ, Chao CH, Xia W, et al: p53
regulates epithelial-mesenchymal transition and stem cell
properties through modulating miRNAs. Nat Cell Biol. 13:317–323.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: mechanism,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
10
|
Hugo H, Ackland ML, Blick T, et al:
Epithelial-mesenchymal and mesenchymal-epithelial transitions in
carcinoma progression. J Cell Physiol. 213:374–383. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Min C, Eddy SF, Sherr DH and Sonenshein
GE: NF-κB and epithelial to mesenchymal transition of cancer. J
Cell Biochem. 104:733–744. 2008.
|
|
12
|
Proksch E, Brandner JM and Jensen JM: The
skin: an indispensable barrier. Exp Dermatol. 17:1063–1072. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Laird DW: Life cycle of connexins in
health and disease. J Biochem. 394:527–543. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cronier L, Crespin S, Strale PO, Defamie N
and Mesnil M: Gap junctions and cancer: new functions for an old
story. Antioxid Redox Signal. 11:323–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Plante I, Stewart MK, Barr K, Allan AL and
Laird DW: Cx43 suppresses mammary tumor metastasis to the lung in a
Cx43 mutant mouse model of human disease. Oncogene. 30:1681–1692.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogawa K, Pitchakarn P, Suzuki S, et al:
Silencing of connexin 43 suppresses invasion, migration and lung
metastasis of rat hepatocellular carcinoma cells. Cancer Sci.
103:860–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Willecke K, Eiberger J, Degen J, et al:
Structural and functional diversity of connexin genes in the mouse
and human genome. Biol Chem. 383:725–737. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okuma A, Kuraoka A, Iida H, Inai T, Wasano
K and Shibata Y: Colocalization of connexin 43 and connexin 45 but
absence of connexin 40 in granulosa cell gap junctions of rat
ovary. J Reprod Fertil. 107:255–264. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Risley MS, Tan IP, Roy C and Saez JC:
Cell-, age- and stage dependent distribution of connexin43 gap
junctions in testes. J Cell Sci. 103:81–96. 1992.PubMed/NCBI
|
|
20
|
de Oliveira KD, Tedardi MV, Cogliati B and
Dagli ML: Higher incidence of lung adenocarcinomaa induced by DMBA
in Cx43 heterozygous knockout mice. Biomed Res Int.
2013:6184752013. View Article : Google Scholar
|
|
21
|
Zhao W, Han HB and Zhang ZQ: Suppression
of lung cancer cell invasion and metastasis by Cx43 involves the
secretion of follistatin-like 1 mediated via histone acetylation.
Int J Biochem Cell Biol. 43:1459–1468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu HT, Li QC, Zhang YX, et al: Cx43
recruits E-cadherin expression and inhibits the malignant behaviour
of lung cancer cells. Folia Histochem Cytobiol. 46:315–321.
2008.PubMed/NCBI
|
|
23
|
Zhang YX, Xu HT, Qi FJ and Wang EH:
Expression of Cx43 in lung cancer and its correlation with
E-cadherin. Zhonghua Bing Li Xue Za Zhi. 35:339–343. 2006.(In
Chinese).
|
|
24
|
Chen Q, Qian B, Yang L and Jiang Z: The
expression of Cx43 protein in non-small cell lung cancer tissues
and its clinical significance. Zhongguo Fei Ai Za Zhi. 6:272–274.
2003.(In Chinese).
|
|
25
|
Cesen-Cummings K, Fernstrom MJ, Malkinson
AM and Ruch RJ: Frequent reduction of GJIC and Cx43 expression in
human and mouse lung carcinoma cells. Carcinogenesis. 19:61–67.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin Z, Zhang Z and Wang N: Inhibition of
in vivo growth of lung carcinoma cells after transfetion with gap
junction gene Cx43. Zhonghua Zhong Liu Za Zhi. 19:253–255. 1997.(In
Chinese).
|
|
27
|
Du G, Yang Y, Zhang Y, et al:
Thrombocytosis and immunohistochemical expression of connexin43 at
diagnosis predict survival in advanced non-small-cell lung cancer
treated with cisplatin-based chemotherapy. Cancer Chemother
Pharmacol. 71:893–904. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Sharma S, Hershman JM, Brent GA,
Dubinett SM and Huang M: Iodide sensitizes genetically modified
non-small cell lung cancer cells to ionizing radiation. Cancer Gene
Ther. 13:74–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu ML, Zhang CL, Yuan DD, Tong XH and Tao
L: Panax notoginseng saponins enhances the cytotoxicity of
cisplatin via increasing gap junction intercellular communication.
Biol Pharm Bull. 35:1230–1237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim KS, Yao L, Lee YC, et al:
Hyul-Tong-Ryung suppresses PMA-induced MMP-9 expression by
inhibiting AP-1-mediated gene expression via ERK1/2 signaling
pathway in MCF-7 human breast cancer cells. Immunopharmacol
Immunotoxicol. 32:600–606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar
|
|
32
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tan J, You Y, Xu T, et al: Par-4
downregulation confers cisplatin resistance in pancreatic
cancercells via PI3K/Akt pathway-dependent EMT. Toxicol Lett.
224:7–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kitamura K, Seike M, Okano T, et al:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer
Ther. 13:444–453. 2014.PubMed/NCBI
|
|
35
|
Wu Q, Wang R, Yang Q, et al:
Chemoresistance to gemcitabine in hepatoma cells induces
epithelial-mesenchymal transition and involves activation of PDGF-D
pathway. Oncotarget. 4:1999–2009. 2013.PubMed/NCBI
|
|
36
|
Haslehurst AM, Koti M, Dharsee M, et al:
EMT transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : 2012.
|
|
37
|
Sato H, Iwata H, Takano Y, et al: Enhanced
effect of Cx43 on cisplatin-induced cytotoxicity in mesothelima
cells. J Pharmacol Sci. 110:466–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hong X, Wang Q, Yang Y, et al: Gap
junctions propagate opposite effects in normal and tumor testicular
cells in response to cisplatin. Cancer Lett. 317:165–171. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang RP, Hossain MZ, Huang R, Gano J, Fan
Y and Boynton AL: Connexin 43 (cx43) enhances chemotherapy-induce
apoptosis in human glioblastoma cells. Int J Cancer. 92:130–138.
2001. View Article : Google Scholar : PubMed/NCBI
|
